Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other solid neoplasm 1

Conditions

Lymphoma 725Lymphoma, Non-Hodgkin 659Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Lymphoma, Mantle-Cell 345Burkitt Lymphoma 306Leukemia 304Leukemia, Myeloid, Acute 298Hodgkin Disease 294Lymphoma, B-Cell 281Lymphoma, B-Cell, Marginal Zone 267Recurrence 246Multiple Myeloma 205Neoplasms 200Myelodysplastic Syndromes 171Lymphoma, T-Cell, Cutaneous 171Lymphoma, Large-Cell, Immunoblastic 160Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Waldenstrom Macroglobulinemia 146Lymphoma, Large-Cell, Anaplastic 142Mycosis Fungoides 132Sezary Syndrome 119Immunoblastic Lymphadenopathy 108Blast Crisis 92Hematologic Neoplasms 91Lymphoma, T-Cell, Peripheral 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Lymphoma, T-Cell 82

Interventions

zanubrutinib 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × B-cell Malignancies × Lymphoid × Clear all
NCT01905813 2026-05-11

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Incyte Corporation

Phase 1 Completed
121 enrolled
Lymphoid

B-cell Malignancies

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

NCT06958679 2025-05-14

Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 1 Recruiting
132 enrolled
LymphoidOther solid neoplasm

B-cell Malignancies

NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡